Safety and efficacy of SNS-301 plus pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN)

被引：0
|
作者：
Algazi, Alain Patrick
Smith, William
Bruce, Justine Yang
Shin, Dong Moon
Gramza, Ann Wild
Jelinek, Michael J.
Singh, Jaswinder
Misiukiewicz, Krzysztof
Shah, Dhaval
Campbell, Jean S.
Pierce, Robert Hamilton
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] NOCCR VRG, Knoxville, TN USA
[3] Univ Wisconsin, Madison, WI USA
[4] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[5] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA
[6] Rush Univ, Med Ctr, Chicago, IL 60612 USA
[7] Res Med Ctr, Mission Hills, KS USA
[8] Icahn Sch Med Mt Sinai, Hematol & Med Oncol, New York, NY 10029 USA
[9] Med Oncol Hematol Consultants, Newark, DE USA
[10] Sensei Biotherapeut, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18009
引用
收藏
页数：1
相关论文
共 50 条
  • [31] New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN)
    Mark Agulnik
    Medical Oncology, 2012, 29 : 2481 - 2491
  • [32] New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN)
    Agulnik, Mark
    MEDICAL ONCOLOGY, 2012, 29 (04) : 2481 - 2491
  • [33] Phase II study of 250 mg gefitinib in advanced squamous cell carcinoma of the head and neck (SCCHN).
    Kane, MA
    Cohen, E
    List, M
    Mehrotra, B
    Gustin, D
    Mauer, A
    Cella, D
    Vokes, E
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 509S - 509S
  • [34] Phase I study of gefitinib plus celecoxib in patients with metastatic and/or locally recurrent squamous cell carcinoma of the head and neck (SCCHN).
    Wirth, LJ
    Haddad, RI
    Wieczorek, TJ
    Faucher, JL
    Clark, JR
    Norris, CM
    Posner, MR
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 498S - 498S
  • [35] Phase II study of capecitabine (X) plus reirradiation in patients (PTS) with recurrent squamous cell carcinoma of the head and neck (SCCHN)
    Kornek, Gabriela
    Vormittag, Laurenz
    Burian, Martin
    Radonjic, Dejan
    Selzer, Edgar
    ANNALS OF ONCOLOGY, 2006, 17 : 184 - 184
  • [36] Phase II study of capecitabine (X) plus reirradiation in patients (pts) with recurrent squamous cell carcinoma of the head and neck (SCCHN)
    Kornek, G.
    Burian, M.
    Vormittag, L.
    Radonjic, D.
    Selzer, E.
    EJC SUPPLEMENTS, 2005, 3 (02): : 295 - 295
  • [37] Outcomes of HIV patients treated with chemoradiotherapy (CRT) for squamous cell carcinoma of the head and neck (SCCHN)
    Mourad, Waleed Fouad
    Hu, Kenneth
    Shourbaji, Rania Ayman
    Li, Zujun
    Culliney, Bruce
    Harrison, Louis Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] IMMUNOMODULATION WITH DIETHYLDITHIOCARBAMATE (DDTC) IN PATIENTS WITH RECURRENT SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
    PAREDES, J
    REUBEN, J
    HERSH, EM
    ROBBINS, T
    MCCARTHY, K
    HONG, WK
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1987, 28 : 405 - 405
  • [39] PATIENT REPORTED HRQOL IN PATIENTS WITH STAGE IV SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
    Byrne, K.
    Hallworth, P.
    Zanotti, G.
    VALUE IN HEALTH, 2017, 20 (05) : A120 - A121
  • [40] KEYNOTE-412: Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma
    Siu, Lillian L.
    Licitra, Lisa
    Tao, Yun Gan
    Yen, Chia-Jui
    Rischin, Danny
    Waldron, John
    Burtness, Barbara
    Gregoire, Vincent
    Agarwala, Sanjiv
    Yorio, Jeffrey
    DeLord, Jean-Pierre
    Aksoy, Sercan
    Ikeda, Sadakatsu
    Hong, Ruey-Long
    Ge, Joy Yang
    Brown, Holly
    Bidadi, Behzad
    Machiels, Jean-Pascal
    CANCER RESEARCH, 2018, 78 (13)
12345